New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
08:36 EDTMRK, SSNLF, BIIBMerck, Samsung Bioepis enter collaboration agreement
Merck (MRK) and Samsung Bioepis, a joint venture between Samsung (SSNLF) Biologics and Biogen (BIIB), announced that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. Under the terms of the agreement, the companies will collaborate on clinical development, regulatory filings and manufacturing. If approved, Merck will commercialize this candidate. This collaboration builds on the agreement made by the two companies in February 2013 to develop and commercialize multiple biosimilar candidates.
News For MRK;SSNLF;BIIB From The Last 14 Days
Check below for free stories on MRK;SSNLF;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 24, 2014
05:03 EDTSSNLFAT&T to offer Samsung Gear S
Subscribe for More Information
September 23, 2014
12:58 EDTSSNLFSamsung still supplying 40% of A8 chips for iPhone 6, 6 Plus, Re/code says
Subscribe for More Information
07:33 EDTMRKOphthotech names Michael Atieh as EVP, Chief Financial and Business Officer
Ophthotech Corporation (OPHT) announced that Michael G. Atieh has been named EVP, Chief Financial and Business Officer and Treasurer effective September 30. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the company of his intention to retire effective September 30. Atieh spent the majority of his career in the pharmaceutical industry with Merck and Co (MRK), where he held various senior level positions over a 20 year period including Senior Vice President-Merck Medco Managed Care, Vice President-U.S. Human Health, Vice President-Public Affairs, Vice President-Government Relations, and Treasurer.
07:28 EDTSSNLFBlackBerry prices 'Passport' below competing high-end smartphones, WSJ says
BlackBerry, whose Passport smartphone marks its first global launch since its BB10 operating system, is pricing the new phone at $599 in the U.S. without subsidies, which is below Apple's (AAPL) iPhone 6, which starts at $649 without contract, and Samsung's (SSNLF) Galaxy S5, which was similarly priced at about $650 at launch, reported The Wall Street Journal. Reference Link
September 22, 2014
07:21 EDTBIIBEBD Group to hold a conference
Subscribe for More Information
06:51 EDTMRKMerck to host conference call
Subscribe for More Information
06:34 EDTSSNLFGoogle selects HTC to make 9-inch Nexus tablet, WSJ reports
Subscribe for More Information
September 19, 2014
10:59 EDTSSNLFSamsung working with PayPal for mobile payments on smartwatch, Gigaom says
Subscribe for More Information
September 18, 2014
08:48 EDTMRKNeogen's dairy genomic program to be marketed by Merck
Subscribe for More Information
07:26 EDTSSNLFGartner: Smartwatch market ready to expand, poised for takeoff, DigiTimes says
Subscribe for More Information
06:45 EDTSSNLFMobile DRAM bit growth to reach 37.5% in 2H14, DigiTimes Research reports
Subscribe for More Information
September 17, 2014
09:33 EDTMRKMerck announced positive results from Phase 3 data for omarigliptin
Subscribe for More Information
08:31 EDTMRKMerck, Sun Pharma enter into licensing agreement for Tildrakizumab
Merck and Sun Pharmaceutical Industries, through their respective subsidiaries,announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80M. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. Merck is eligible to receive undisclosed payments associated with regulatory and sales milestones, as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales. The transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.
06:31 EDTSSNLFLG Display to supply AMOLED panels for Apple Watch, DigiTimes reports
LG Display (LPL) are expected to supply Apple (AAPL) 5M AMOLED panels a month in 2015 for the Apple Watch, reports DigiTimes. According to sources from LG Display, Apple aims to sell upwards of 50M Apple Watches in 2015. Apple will reportedly not purchase AMOLED panels from Samsung (SSNLF) Display and instead will have LG as the sole panel provider for the Apple Watch. Reference Link
06:21 EDTSSNLFLCD TV shipments expected to grow 3%-5% through 2017, DigiTimes reports
Subscribe for More Information
September 16, 2014
10:52 EDTSSNLFApple, China Mobile trade lower as iPhone 6 unlikely to debut in China this year
Subscribe for More Information
09:13 EDTSSNLFApple may need to wait until 2015 to launch iPhone 6 in China, Bloomberg says
Subscribe for More Information
07:31 EDTMRKEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:25 EDTMRKMerck price target raised to $72 from $62 at SunTrust
After meeting with Merck's CEO and head of clinical development, SunTrust increased its price target on the company as the firm thinks that it is ideally positioned across five of the fastest growing therapeutic classes. The firm believes that the company's EPS growth rates from 2015-2020 will be three percentage points above Street estimates, while it has a first-mover advantage in oncology. It keeps a Buy rating on the shares.
06:28 EDTSSNLFLenovo, Huawei look to pose threat in high-end smartphone segment, DigiTimes says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use